

Ontex posts EBITDA of €150.3 million for 2009

Zele, Belgium, May 25, 2010

Ontex, Europe's market leader in private label hygienic disposables, is pleased to announce recurring EBITDA¹ of \in 150.3 million for the year ended December 31, 2009 (as compared to \notin 94.8 million in 2008).

Since its appointment in 2006, management has focused on customer service and profitability rather than sales volume growth. The increase in recurring EBITDA reflects the enhanced operational integration of the Group's various businesses through the optimisation of manufacturing and logistic flows, more efficient raw material purchasing and customerfocused product development.

Sales across Ontex's three divisions – Retail, Healthcare, and Turkey Regional totalled €1.104 billion in 2009 (€1.109 billion in 2008).

The **Retail Division** primarily supplies private label products including disposable diapers, feminine care products and adult incontinence products to retailers, including each of Europe's top ten retailers.

The **Healthcare division** principally supplies the healthcare market including institutions such as hospitals and health authorities.

The **Turkey Regional Division** principally supplies branded baby care, adult incontinence, and feminine care products to the Turkish retail market and surrounding countries.

Michael Teacher, Ontex's Chief Executive Officer said: "We are pleased with our performance in 2009, which is particularly positive when viewed in the context of a difficult economic trading environment. The measures we have implemented to improve operational efficiencies are bearing fruit and our strong EBITDA performance in 2009 reflects this. Ontex has a broad product portfolio, manufactured across its 12 production facilities, 9 of which are located in Western Europe and the remainder in Turkey, Algeria and China. We believe the business is well-placed for further growth in 2010."

<u>Contact:</u> Ontex International NV +32-52 454.603 Chris Parratt, Chief Financial Officer <u>www.ontex.eu</u>

¹ Calculated by adding back non-recurring expenses to reported EBITDA